Personalis, Inc.

Personalis, Inc. is at the forefront of personalized and precision cancer care. The company focuses on developing advanced genomic testing and analytics to detect cancer recurrence earlier and with higher sensitivity. Their flagship product, NeXT Personal, offers ultra-sensitive liquid biopsy tests that can identify cancer recurrence before traditional scans. Personalis works closely with healthcare professionals and biopharma partners to enhance treatment strategies and is committed to revolutionizing cancer care through innovative biomarker analysis and personalized cancer treatments.